341 related articles for article (PubMed ID: 11726831)
21. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
22. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients.
Cole E; Landsberg D; Russell D; Zaltzman J; Kiberd B; Caravaggio C; Vasquez AR; Halloran P
Transplantation; 2001 Sep; 72(5):845-50. PubMed ID: 11571448
[TBL] [Abstract][Full Text] [Related]
24. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.
Kato T; Gaynor JJ; Yoshida H; Montalvano M; Takahashi H; Pyrsopoulos N; Nishida S; Moon J; Selvaggi G; Levi D; Ruiz P; Schiff E; Tzakis A
Transplantation; 2007 Oct; 84(7):829-35. PubMed ID: 17984834
[TBL] [Abstract][Full Text] [Related]
26. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients.
Ciancio G; Burke GW; Suzart K; Mattiazzi A; Vaidya A; Roth D; Kupin W; Rosen A; Johnson N; Miller J
Am J Transplant; 2003 Aug; 3(8):1010-6. PubMed ID: 12859538
[TBL] [Abstract][Full Text] [Related]
27. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
[TBL] [Abstract][Full Text] [Related]
28. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
29. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I
Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416
[TBL] [Abstract][Full Text] [Related]
30. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
[TBL] [Abstract][Full Text] [Related]
31. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
Ekberg H; Persson NH; Källen R; Gül-Baykurt N
Scand J Immunol; 2003 Dec; 58(6):670-7. PubMed ID: 14636424
[TBL] [Abstract][Full Text] [Related]
32. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
[TBL] [Abstract][Full Text] [Related]
33. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O
Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528
[TBL] [Abstract][Full Text] [Related]
34. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
35. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
[TBL] [Abstract][Full Text] [Related]
36. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
[TBL] [Abstract][Full Text] [Related]
37. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
38. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
39. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
40. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
